摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-三氟甲基环丙烷-1-甲酸乙酯 | 139229-57-5

中文名称
1-三氟甲基环丙烷-1-甲酸乙酯
中文别名
1-三氟甲基环丙甲酸乙酯
英文名称
ethyl 1-(trifluoromethyl)cyclopropane-1-carboxylate
英文别名
Ethyl 1-(trifluoromethyl)cyclopropanecarboxylate
1-三氟甲基环丙烷-1-甲酸乙酯化学式
CAS
139229-57-5
化学式
C7H9F3O2
mdl
MFCD22199506
分子量
182.142
InChiKey
XKNRIQDQYMPZKZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    127.4±35.0 °C(Predicted)
  • 密度:
    1.311±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.857
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    5

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    2-8°C

SDS

SDS:9ff1db9f726b621f32017e5a45351cf4
查看

反应信息

  • 作为反应物:
    描述:
    1-三氟甲基环丙烷-1-甲酸乙酯1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 sodium hydride 、 sodium carbonate 、 硫酸羟胺N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下, 以 四氢呋喃甲醇N,N-二甲基甲酰胺乙腈 为溶剂, 反应 32.0h, 生成 2-(4-(6-aminopyridin-3-yl)-2-fluorophenyl)-N-(5-(1-(trifluoromethyl)cyclopropyl)isoxazol-3-yl)acetamide
    参考文献:
    名称:
    Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors
    摘要:
    Based on a putative binding mode of quizartinib (AC220, 1), a potent FMS-like tyrosine kinase 3 (FLT3) inhibitor in Phase III clinical development, we have designed de novo a simpler aminopyridine-based hinge binding motif. Further optimization focusing on maximizing in vivo efficacy and minimizing CYP3A4 time-dependent inhibition resulted in a highly efficacious compound (6s) in tumor xenograft model for further preclinical development. (C) 2015 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2015.07.023
  • 作为产物:
    描述:
    1,1-环丙基二羧酸二乙酯氢氧化钾 、 sulfur tetrafluoride 作用下, 以 乙醇 为溶剂, 反应 27.0h, 生成 1-三氟甲基环丙烷-1-甲酸乙酯
    参考文献:
    名称:
    环丙烷羧酸衍生物与四氟化硫的反应-非对映选择性开环的一个例子
    摘要:
    可以使用SF 4将环丙烷羧酸衍生物转化为含三氟甲基的化合物。在双环环丙烷羧酸内酯的情况下,用四氟化硫的类似处理导致以非对映选择性的方式打开环丙烷环。
    DOI:
    10.1016/s0022-1139(00)00257-8
点击查看最新优质反应信息

文献信息

  • Deoxofluorination of Aliphatic Carboxylic Acids: A Route to Trifluoromethyl-Substituted Derivatives
    作者:Maksym Bugera、Serhii Trofymchuk、Karen Tarasenko、Olga Zaporozhets、Yurii Pustovit、Pavel K. Mykhailiuk
    DOI:10.1021/acs.joc.9b02596
    日期:2019.12.20
    A practical method for the synthesis of functionalized aliphatic trifluoromethyl-substituted derivatives from aliphatic acids is developed. The transformation proceeds with sulfur tetrafluoride in the presence of water as a key additive. Compared to previous methods, the reaction gives products with full retention of stereo- and absolute configuration of chiral centers.
    开发了一种由脂族酸合成官能化脂族三氟甲基取代衍生物的实用方法。在有水作为关键添加剂的情况下,用四氟化硫进行转化。与以前的方法相比,该反应使产物完全保留了手性中心的立体构型和绝对构型。
  • Ortho-substituted benzyl esters of cyclopropanecarboxylic acids
    申请人:BASF Aktiengesellschaft
    公开号:US05371268A1
    公开(公告)日:1994-12-06
    Ortho-substituted benzyl esters of cyclopropanecarboxylic acids I ##STR1## where X is N or CH and A is one of the following cyclopropane radicals: ##STR2## where R.sup.1 is CN, C.sub.2 -C.sub.8 -alkyl, CF.sub.3, C.sub.3 -C.sub.8 -alkenyl, (C.sub.1 -C.sub.4 -alkoxycarbonyl, unsubstituted or substituted phenyl-C.sub.1 -C.sub.6 -alkyl or phenyl-C.sub.3 -C.sub.6 -alkenyl, ethoxyphenyl, 2- or 3-bromophenyl, 2- or 4-trifluoromethylphenyl, 2,4- or 2,6-difluorophenyl, 2-fluoro-6-chlorophenyl, 2,4- or 2,6-dimethylphenyl, 2,3,6-trichlorophenyl or trimethylsilyl, R.sup.2 is H or halogen, R.sup.3 is unsubstituted or substituted phenyl, R.sup.4 is CH.sub.3 or halogen and Hal is halogen, with the proviso that X is CH when R.sup.1 is CF.sub.3 or trimethylsilyl, are suitable as fungicides and for controlling pests.
    对环丙烷羧酸的邻位取代苄基酯I ##STR1##,其中X为N或CH,A为以下环丙烷基团之一:##STR2##其中R.sup.1为CN、C.sub.2-C.sub.8-烷基、CF.sub.3、C.sub.3-C.sub.8-烯基、(C.sub.1-C.sub.4-烷氧羰基、未取代或取代的苄基或苄基烯基苯基、乙氧基苯基、2-或3-溴苯基、2-或4-三氟甲基苯基、2,4-或2,6-二氟苯基、2-氟-6-氯苯基、2,4-或2,6-二甲基苯基、2,3,6-三氯苯基或三甲基硅基,R.sup.2为H或卤素,R.sup.3为未取代或取代的苯基,R.sup.4为CH.sub.3或卤素,Hal为卤素,但X为CH时,R.sup.1为CF.sub.3或三甲基硅基,适用于杀菌剂和害虫控制剂。
  • [EN] SULPHONAMIDE COMPOUNDS<br/>[FR] COMPOSÉS SULFONAMIDES
    申请人:ANAXIS PHARMA PTY LTD
    公开号:WO2021253095A1
    公开(公告)日:2021-12-23
    This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.
    该发明涉及式(I)化合物及其盐、溶剂合物、互变异构体、N-氧化物、立体异构体、多晶形态和/或前药的用途。还公开了利用式(I)化合物治疗坏死程序和/或抑制MLKL的方法。
  • Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
    申请人:University of Pittsburgh—Of the Commonwealth System of Higher Education
    公开号:US10980806B2
    公开(公告)日:2021-04-20
    A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20—(Z)b—(Y)c—(R21)a—(X)d—R22—R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), —S(═O)(═O)—, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, cycloalkenediyl, substituted cycloalkenediyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; R22 includes at least one divalent amino radical; R23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.
    一种符合式 I 的化合物或其药学上可接受的盐或酯: R20-(Z)b-(Y)c-(R21)a-(X)d-R22-R23 其中 R20 是芳基、取代的芳基、杂芳基、取代的杂芳基、环烷基、取代的环烷基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硫基的基团或含硒基的基团;Z 是烷二基、取代的烷二基、环烷二基或取代的环烷二基; Y 是 S、O、S(═O)、-S(═O)(═O)- 或 NR10,其中 R10 是 H 或烷基;R21是烷二基、取代的烷二基、环烷二基、取代的环烷二基、烷二烯基、取代的烷二烯基、环烷二基、取代的环烷二基、烷三烯基、取代的烷三烯基;X是-C(═O)-、-S(═O)(═O)-或-N(H)C(═O)-;R22 包括至少一个二价氨基; R23 是芳基、取代的芳基、杂芳基、取代的杂芳基、环烷基、取代的环烷基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硫醚基团或含硒基团;a、b、c 和 d 独立地为 0 或 1。
  • Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators
    作者:Swagat Sharma、Krystian A. Kozek、Kristopher K. Abney、Sushil Kumar、Nagsen Gautam、Yazen Alnouti、C. David Weaver、Corey R. Hopkins
    DOI:10.1016/j.bmcl.2019.01.027
    日期:2019.3
    The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物